Global health trends show rising chronic disease burdens alongside shifts in treatment approaches, from skin cancer projections to GLP-1 drug adoption displacing surgery, while emerging injuries from urban mobility devices strain emergency care systems.

Global skin cancer burden has increased significantly from 1990 to 2023 and is projected to continue rising through 2050, according to database analysis, highlighting a major public health concern.

GLP-1 drug prescriptions surged by more than 140% from 2022 through 2024, while metabolic bariatric surgery rates declined 34.1% during the same period, indicating a major shift in obesity treatment approaches.

Semaglutide demonstrated substantial weight loss and cardiometabolic improvements in adults aged 65 and older in pooled STEP trial analysis, expanding evidence for GLP-1 effectiveness in elderly populations with obesity.

Early-onset colorectal cancer among younger Americans continues to rise, with two new studies identifying previously unknown risk factors contributing to this concerning trend.

Preeclampsia increases the risk of chronic hypertension development in the decade following pregnancy, yet postpartum follow-up care for affected women remains inadequate.

Inavolisib benefits persist in PIK3CA-mutated breast cancer patients regardless of hyperglycemia side effects, with exploratory data showing numerically better outcomes in patients who develop this metabolic complication.

Patients with psoriatic arthritis who have inadequate TNF inhibitor response, particularly those with elevated C-reactive protein, may benefit from combination therapy with guselkumab plus golimumab.

Emergency departments in Rome and New York are experiencing increased fractures and head injuries linked to electric scooters and e-bikes, with low helmet usage rates exacerbating trauma unit strain in urban centers.